PEN — Penumbra Inc
—
NYSE ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1321732 ·
Last close
$318.71
Market Cap
$12.54B
52W High
$338.98
52W Low
$317.53
ADV30
432,507
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 374,758,000 | 253,411,000 | 38,234,000 | 32,584,000 | 1,898,438,000 | 241,289,000 | 424,626,000 |
| Dec 2025 | 385,385,000 | 262,128,000 | 59,233,000 | 47,343,000 | 1,826,519,000 | 186,897,000 | 398,916,000 |
| Sep 2025 | 354,685,000 | 240,416,000 | 48,838,000 | 45,851,000 | 1,744,369,000 | 321,029,000 | 385,673,000 |
| Jun 2025 | 339,455,000 | 224,010,000 | 40,828,000 | 45,270,000 | 1,674,809,000 | 421,768,000 | 380,858,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$276,664,000
Investing CF
$-434,721,000
Financing CF
$21,917,000
CapEx
$-63,933,000
Dividends Paid
—
Buybacks
$1,000
EPS Diluted TTM
$4.34
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$270,275,000
Inventory
$438,539,000
Receivables
$183,295,000
ST Investments
$374,371,000
EBIT TTM
$204,262,000
Pretax Income TTM
$202,955,000
Interest Exp TTM
$1,307,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,454,283,008
EBITDA
$203,963,008
Free Cash Flow
$141,799,872
Enterprise Value
$12,135,833,600
Total Cash
$615,660,032
Total Debt
$216,175,008
Shares Out
39,331,425
Trailing EPS
$4.33
Book Value
$37.48
ROE
12.7%
ROA
6.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,403,665,000 | 189,249,000 | 177,687,000 | 1,826,519,000 | 398,916,000 | — | 238,663,000 |
| Dec 2024 | 1,194,615,000 | 86,224,000 | 14,012,000 | 1,533,181,000 | 382,250,000 | — | 168,481,000 |
| Dec 2023 | 1,058,522,000 | 91,766,000 | 90,954,000 | 1,556,305,000 | 377,361,000 | — | 97,333,000 |
| Dec 2022 | 847,133,000 | 6,082,000 | -2,002,000 | 1,370,886,000 | 372,028,000 | — | -55,661,000 |
TTM Snapshot
Revenues TTM
$975,780,000
NetIncome TTM
$45,320,000
OpCashFlow TTM
$0
Assets (Latest)
$1,533,181,000
Forward EPS
$6.29
Max Pain — expiry 2027-01-15
max pain strike: $380.00 · spot: $317.67 · call oi: 1,567 · put oi: 3,622
Expected Move to 2027-01-15:
±$124.00
(39.03%) —
implied range
$193.67 –
$441.67
· ATM straddle on $320.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALGN | ALIGN TECHNOLOGY INC | $12.52B | $174.84 | — |
| SNNUF | SMITH & NEPHEW PLC | $12.79B | $15.10 | — |
| SNN | SMITH & NEPHEW PLC | $12.95B | $30.57 | — |
| SOLV | Solventum Corp | $13.66B | $78.87 | — |
| BAX | BAXTER INTERNATIONAL INC | $10.77B | $20.86 | — |
News headlines (Yahoo Finance, 1h cache)
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
2026-06-15 13:00 · Yahoo
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance
2026-06-13 07:17 · Yahoo
FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke
2026-06-12 15:34 · Yahoo
Penumbra's Thunderbolt Device Offers Revenue Upside Not Reflected in Estimates, RBC Says
2026-06-12 14:52 · Yahoo
Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
2026-06-12 11:22 · Yahoo
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
2026-06-11 20:05 · Yahoo
GMED or PEN: Which Is the Better Value Stock Right Now?
2026-06-05 15:40 · Yahoo
Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?
2026-06-05 15:30 · Yahoo
Here’s What Supports Penumbra’s (PEN) Revenue Growth and Margin Expansion
2026-06-05 13:14 · Yahoo
Boston Scientific Bets on Growth Through Strategic M&A Deals
2026-05-18 18:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.